CVS Group
CVSG · Main Market · Health Care · mcap £863m · 1317.0p 2 open situations →
Open · 2
Buyback programme
Began in October 2025 as a £20m buyback funded from headroom, with leverage at 1.18x. After the CMA final decision and the bank refinancing, the Board launched up to £50m. This announcement starts it: Peel Hunt and Berenberg buy and cancel shares, with completion expected by 24 November 2026.
- Size
- Up to £50m, shares bought on the London Stock Exchange and other venues, then cancelled
- Brokers
- Peel Hunt LLP and Joh. Berenberg, Gossler & Co. KG, London Branch, as riskless principals, trading independently of the Company
- Leverage policy
- No more than 2.0x bank test net debt / bank test EBITDA
- Next milestone
- Further announcement on maximum shares and terms; capital allocation presentation on 23 July 2026
- Authority
- AGM authority of 18 November 2025; 6,040,012 shares remain available for purchase
- Purpose
- Return surplus capital to shareholders and reduce share capital under the capital allocation policy
Next: Completion of buyback; capital allocation presentation · 24 Nov 2026
- 26 May 2026 announced
- 26 May 2026 announced
CEO succession
CEO Richard Fairman announced his retirement on 30 March 2026 and stays until a successor is found. The search was early stage on 26 May 2026, and nothing more was said on 23 July 2026. The 24 Sep 2026 results add no appointment or timetable; he remains committed to leading CVS until a successor arrives.
- Board view
- Thorough search under way; update when appropriate 23 Jul 2026 ↗
- CEO
- Richard Fairman remains committed to leading CVS until a successor takes up the role 24 Sep 2026 ↗
- Appointment
- No successor or timetable announced 24 Sep 2026 ↗
Next: Appoint successor to Richard Fairman
- 24 Sep 2026 Search ongoing, no appointment yet
- 23 Jul 2026 Search ongoing, no appointment yet
- 26 May 2026 Search at early stages
- 30 Mar 2026 Search to be initiated; Fairman stays until successor
Closed · 1
Company filings. Not investment advice.